View in EDS HTML Full Text PDF Full Text

Coprescription of mood stabilizers in schizophrenia, dosing, and clinical correlates: An international study.

Saved in:
Bibliographic Details
Title: Coprescription of mood stabilizers in schizophrenia, dosing, and clinical correlates: An international study.
Authors: Lim, Wai Kwong (AUTHOR), Chew, Qian Hui (AUTHOR), He, Yan‐Ling (AUTHOR), Si, Tian‐Mei (AUTHOR), Chiu, Fung‐Kum Helen (AUTHOR), Xiang, Yu‐Tao (AUTHOR), Kato, Takahiro A. (AUTHOR), Kanba, Shigenobu (AUTHOR), Shinfuku, Naotaka (AUTHOR), Lee, Min‐Soo (AUTHOR), Park, Seon‐Cheol (AUTHOR), Park, Yong‐Chon (AUTHOR), Chong, Mian‐Yoon (AUTHOR), Lin, Shih‐Ku (AUTHOR), Yang, Shu‐Yu (AUTHOR), Tripathi, Adarsh (AUTHOR), Avasthi, Ajit (AUTHOR), Grover, Sandeep (AUTHOR), Kallivayalil, Roy Abraham (AUTHOR), Udomratn, Pichet (AUTHOR)
Source: Human Psychopharmacology: Clinical & Experimental. Nov2020, Vol. 35 Issue 6, p1-7. 7p.
Subjects: Mood stabilizers, Aripiprazole, Schizophrenia, Body mass index, Psychoses, Amisulpride, Symptoms
Geographic Terms: Asia
Abstract: Objective: Studies examining coprescription and dosages of mood stabilizers (MSs) with antipsychotics for psychotic disorders are infrequent. Based on sparse extant data and clinical experience, we hypothesized that adjunctive MS use would be associated with certain demographic (e.g., younger age), clinical factors (e.g., longer illness duration), and characteristics of antipsychotic treatment (e.g., multiple or high antipsychotic doses). Methods: Within an Asian research consortium focusing on pharmaco‐epidemiological factors in schizophrenia, we evaluated rates of MS coprescription, including high doses (>1000 mg/day lithium‐equivalents) and clinical correlates. Results: Among 3557 subjects diagnosed with schizophrenia in 14 Asian countries, MSs were coprescribed with antipsychotics in 13.6% (n = 485) of the sample, with 10.9% (n = 53) on a high dose. Adjunctive MS treatment was associated (all p < 0.005) with demographic (female sex and younger age), setting (country and hospitalization), illness (longer duration, more hospitalizations, non‐remission of illness, behavioral disorganization, aggression, affective symptoms, and social–occupational dysfunction), and treatment‐related factors (higher antipsychotic dose, multiple antipsychotics, higher body mass index, and greater sedation). Patients given high doses of MSs had a less favorable illness course, more behavioral disorganization, poorer functioning, and higher antipsychotic doses. Conclusions: Schizophrenia patients receiving adjunctive MS treatment in Asian psychiatric centers are more severely ill and less responsive to simpler treatment regimens. [ABSTRACT FROM AUTHOR]
Copyright of Human Psychopharmacology: Clinical & Experimental is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 146927730
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Coprescription of mood stabilizers in schizophrenia, dosing, and clinical correlates: An international study.
– Name: Author
  Label: Authors
  Group: Au
  Data: &lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Lim%2C+Wai+Kwong%22&quot;&gt;Lim, Wai Kwong&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Chew%2C+Qian+Hui%22&quot;&gt;Chew, Qian Hui&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22He%2C+Yan‐Ling%22&quot;&gt;He, Yan‐Ling&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Si%2C+Tian‐Mei%22&quot;&gt;Si, Tian‐Mei&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Chiu%2C+Fung‐Kum+Helen%22&quot;&gt;Chiu, Fung‐Kum Helen&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Xiang%2C+Yu‐Tao%22&quot;&gt;Xiang, Yu‐Tao&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Kato%2C+Takahiro+A%2E%22&quot;&gt;Kato, Takahiro A.&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Kanba%2C+Shigenobu%22&quot;&gt;Kanba, Shigenobu&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Shinfuku%2C+Naotaka%22&quot;&gt;Shinfuku, Naotaka&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Lee%2C+Min‐Soo%22&quot;&gt;Lee, Min‐Soo&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Park%2C+Seon‐Cheol%22&quot;&gt;Park, Seon‐Cheol&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Park%2C+Yong‐Chon%22&quot;&gt;Park, Yong‐Chon&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Chong%2C+Mian‐Yoon%22&quot;&gt;Chong, Mian‐Yoon&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Lin%2C+Shih‐Ku%22&quot;&gt;Lin, Shih‐Ku&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Yang%2C+Shu‐Yu%22&quot;&gt;Yang, Shu‐Yu&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Tripathi%2C+Adarsh%22&quot;&gt;Tripathi, Adarsh&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Avasthi%2C+Ajit%22&quot;&gt;Avasthi, Ajit&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Grover%2C+Sandeep%22&quot;&gt;Grover, Sandeep&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Kallivayalil%2C+Roy+Abraham%22&quot;&gt;Kallivayalil, Roy Abraham&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Udomratn%2C+Pichet%22&quot;&gt;Udomratn, Pichet&lt;/searchLink&gt; (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: &lt;searchLink fieldCode=&quot;JN&quot; term=&quot;%22Human+Psychopharmacology%3A+Clinical+%26+Experimental%22&quot;&gt;Human Psychopharmacology: Clinical &amp; Experimental&lt;/searchLink&gt;. Nov2020, Vol. 35 Issue 6, p1-7. 7p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: &lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Mood+stabilizers%22&quot;&gt;Mood stabilizers&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Aripiprazole%22&quot;&gt;Aripiprazole&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Schizophrenia%22&quot;&gt;Schizophrenia&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Body+mass+index%22&quot;&gt;Body mass index&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Psychoses%22&quot;&gt;Psychoses&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Amisulpride%22&quot;&gt;Amisulpride&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Symptoms%22&quot;&gt;Symptoms&lt;/searchLink&gt;
– Name: SubjectGeographic
  Label: Geographic Terms
  Group: Su
  Data: &lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Asia%22&quot;&gt;Asia&lt;/searchLink&gt;
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Objective: Studies examining coprescription and dosages of mood stabilizers (MSs) with antipsychotics for psychotic disorders are infrequent. Based on sparse extant data and clinical experience, we hypothesized that adjunctive MS use would be associated with certain demographic (e.g., younger age), clinical factors (e.g., longer illness duration), and characteristics of antipsychotic treatment (e.g., multiple or high antipsychotic doses). Methods: Within an Asian research consortium focusing on pharmaco‐epidemiological factors in schizophrenia, we evaluated rates of MS coprescription, including high doses (&gt;1000 mg/day lithium‐equivalents) and clinical correlates. Results: Among 3557 subjects diagnosed with schizophrenia in 14 Asian countries, MSs were coprescribed with antipsychotics in 13.6% (n = 485) of the sample, with 10.9% (n = 53) on a high dose. Adjunctive MS treatment was associated (all p &lt; 0.005) with demographic (female sex and younger age), setting (country and hospitalization), illness (longer duration, more hospitalizations, non‐remission of illness, behavioral disorganization, aggression, affective symptoms, and social–occupational dysfunction), and treatment‐related factors (higher antipsychotic dose, multiple antipsychotics, higher body mass index, and greater sedation). Patients given high doses of MSs had a less favorable illness course, more behavioral disorganization, poorer functioning, and higher antipsychotic doses. Conclusions: Schizophrenia patients receiving adjunctive MS treatment in Asian psychiatric centers are more severely ill and less responsive to simpler treatment regimens. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: &lt;i&gt;Copyright of Human Psychopharmacology: Clinical &amp; Experimental is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder&#39;s express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.&lt;/i&gt; (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=146927730
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1002/hup.2752
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 7
        StartPage: 1
    Subjects:
      – SubjectFull: Mood stabilizers
        Type: general
      – SubjectFull: Aripiprazole
        Type: general
      – SubjectFull: Schizophrenia
        Type: general
      – SubjectFull: Body mass index
        Type: general
      – SubjectFull: Psychoses
        Type: general
      – SubjectFull: Amisulpride
        Type: general
      – SubjectFull: Symptoms
        Type: general
      – SubjectFull: Asia
        Type: general
    Titles:
      – TitleFull: Coprescription of mood stabilizers in schizophrenia, dosing, and clinical correlates: An international study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Lim, Wai Kwong
      – PersonEntity:
          Name:
            NameFull: Chew, Qian Hui
      – PersonEntity:
          Name:
            NameFull: He, Yan‐Ling
      – PersonEntity:
          Name:
            NameFull: Si, Tian‐Mei
      – PersonEntity:
          Name:
            NameFull: Chiu, Fung‐Kum Helen
      – PersonEntity:
          Name:
            NameFull: Xiang, Yu‐Tao
      – PersonEntity:
          Name:
            NameFull: Kato, Takahiro A.
      – PersonEntity:
          Name:
            NameFull: Kanba, Shigenobu
      – PersonEntity:
          Name:
            NameFull: Shinfuku, Naotaka
      – PersonEntity:
          Name:
            NameFull: Lee, Min‐Soo
      – PersonEntity:
          Name:
            NameFull: Park, Seon‐Cheol
      – PersonEntity:
          Name:
            NameFull: Park, Yong‐Chon
      – PersonEntity:
          Name:
            NameFull: Chong, Mian‐Yoon
      – PersonEntity:
          Name:
            NameFull: Lin, Shih‐Ku
      – PersonEntity:
          Name:
            NameFull: Yang, Shu‐Yu
      – PersonEntity:
          Name:
            NameFull: Tripathi, Adarsh
      – PersonEntity:
          Name:
            NameFull: Avasthi, Ajit
      – PersonEntity:
          Name:
            NameFull: Grover, Sandeep
      – PersonEntity:
          Name:
            NameFull: Kallivayalil, Roy Abraham
      – PersonEntity:
          Name:
            NameFull: Udomratn, Pichet
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 11
              Text: Nov2020
              Type: published
              Y: 2020
          Identifiers:
            – Type: issn-print
              Value: 08856222
          Numbering:
            – Type: volume
              Value: 35
            – Type: issue
              Value: 6
          Titles:
            – TitleFull: Human Psychopharmacology: Clinical & Experimental
              Type: main
ResultId 1